Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Phibro Animal Health is a specialty pharmaceutical and nutritional products company serving global animal health markets across poultry, swine, cattle, and aquaculture. The company operates through three segments: Animal Health (vaccines, medicated feed additives, pharmaceuticals), Mineral Nutrition (trace minerals for feed), and Performance Products (specialty ingredients). With manufacturing facilities in the US, Israel, and Brazil, Phibro serves livestock producers and integrators globally, competing against larger players like Zoetis and Elanco through specialized product portfolios and technical service capabilities.
Phibro generates revenue through direct sales to livestock integrators, feed mills, and distributors globally. The business model relies on technical expertise and regulatory approvals that create switching costs - once producers integrate Phibro's vaccines or feed additives into their protocols, changing suppliers requires revalidation and operational disruption. Pricing power varies by segment: Animal Health products command premium pricing due to efficacy data and regulatory barriers, while Mineral Nutrition faces more commodity-like dynamics tied to raw material costs. The company benefits from recurring revenue as livestock producers require continuous supply of vaccines, antibiotics, and nutritional additives. Geographic diversification across the Americas, EMEA, and Asia-Pacific reduces single-market exposure.
Global livestock production volumes and protein consumption trends - particularly poultry and swine herd sizes in key markets (US, Brazil, China, Southeast Asia)
Animal disease outbreaks (avian influenza, African swine fever, foot-and-mouth disease) that drive vaccine and pharmaceutical demand
Regulatory changes affecting antibiotic use in livestock production (e.g., FDA guidance on medically important antimicrobials, EU restrictions)
Raw material cost inflation for trace minerals (zinc, copper, manganese oxides) and active pharmaceutical ingredients
Acquisition activity and new product launches that expand addressable market or improve product mix
Currency fluctuations given significant international revenue exposure
Regulatory restrictions on antibiotic use in livestock production - FDA and international agencies continue tightening rules on medically important antimicrobials, potentially reducing demand for certain Animal Health products without offsetting growth in alternatives
Consolidation among livestock integrators and feed producers increases customer bargaining power and pricing pressure, particularly in commodity-like Mineral Nutrition segment
Alternative protein technologies (plant-based, cultured meat) could reduce long-term livestock production growth rates in developed markets, though impact timeline remains uncertain
Generic competition as patents expire on proprietary pharmaceutical products, compressing margins in Animal Health segment
Competition from larger, better-capitalized animal health companies (Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim) with broader product portfolios and greater R&D resources for next-generation vaccines and biologics
Vertical integration by large livestock producers developing in-house animal health capabilities or negotiating exclusive supply agreements with major pharmaceutical companies
Commodity pricing pressure in Mineral Nutrition segment from Chinese and other low-cost manufacturers of trace mineral compounds
Elevated leverage with Debt/Equity of 1.82 creates refinancing risk and limits financial flexibility for acquisitions or capacity expansion during industry downturns
Working capital intensity requiring significant inventory investment in raw materials and finished goods, with exposure to obsolescence if disease patterns shift or regulations change
Currency translation risk given international manufacturing footprint and revenue base - USD strength reduces reported earnings from foreign operations
moderate - Livestock production exhibits moderate cyclicality tied to global protein demand, consumer purchasing power, and feed costs. During economic downturns, consumers may shift from premium proteins (beef) to lower-cost options (chicken), affecting product mix. However, animal health spending is relatively non-discretionary as producers must maintain herd health regardless of economic conditions. Emerging market growth drives long-term demand as rising incomes increase meat consumption per capita. Industrial production and agricultural commodity prices influence livestock economics and producer profitability, indirectly affecting animal health spending budgets.
Rising interest rates have modest negative impact through two channels: (1) higher financing costs for the company's debt (Debt/Equity of 1.82 suggests meaningful leverage), increasing interest expense and reducing net margins; (2) increased borrowing costs for livestock producers and integrators, potentially constraining capital spending on herd expansion or facility upgrades. However, animal health products represent small percentages of total livestock production costs, limiting demand elasticity to rate changes. Valuation multiples may compress as rates rise and investors demand higher equity risk premiums.
Moderate credit exposure through customer financing and working capital dynamics. Livestock integrators and feed mills typically operate on thin margins with seasonal cash flow patterns, creating accounts receivable risk during industry downturns or disease outbreaks. The company's 3.05 current ratio suggests adequate liquidity to manage working capital cycles. Credit conditions affect customer ability to finance inventory purchases and capital investments in production facilities that drive long-term animal health product demand.
growth - The 102.5% one-year return and 70.5% six-month return indicate strong momentum, while 27.4% revenue growth and 1,897.7% net income growth (likely reflecting recovery from prior-year challenges) attract growth-oriented investors. The 30.8% ROE suggests improving profitability. However, modest 2.0% FCF yield and reinvestment needs limit appeal to income investors. The stock attracts investors seeking exposure to global protein consumption trends and animal health sector consolidation themes. Recent performance suggests potential turnaround or restructuring success driving multiple expansion.
moderate-to-high - Small-cap healthcare stocks ($2.1B market cap) typically exhibit elevated volatility. Animal health sector faces event-driven volatility from disease outbreaks, regulatory announcements, and commodity price swings. The 70.5% six-month gain indicates significant momentum and potential mean-reversion risk. Limited analyst coverage and lower trading liquidity in small-cap names amplify price movements on earnings surprises or sector rotation.
